Cargando…

Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market

This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.

Detalles Bibliográficos
Autores principales:	Dean, Emma Boswell, Bond, Amelia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796923/ https://www.ncbi.nlm.nih.gov/pubmed/35977178 http://dx.doi.org/10.1001/jamahealthforum.2021.2634

Ejemplares similares

Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients
por: Dean, Emma Boswell, et al.
Publicado: (2021)

Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D
por: Trish, Erin, et al.
Publicado: (2021)

Medicare Spending on Drugs With Accelerated Approval, 2015-2019
por: Rome, Benjamin N., et al.
Publicado: (2021)

Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020
por: Kyle, Michael Anne, et al.
Publicado: (2022)

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
por: Hussaini, S. M. Qasim, et al.
Publicado: (2022)

Analysis of Prescriptions Dispensed After Death and Associated Medicare Spending Following Reimbursement Policy Changes in Medicare
por: Vouri, Scott M., et al.
Publicado: (2023)

Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019
por: Duvalyan, Angela, et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Prescription Drug Coverage and Spending for Medicare Beneficiaries
por: Poisal, John A., et al.
Publicado: (1999)

Outpatient prescription drug spending by the Medicare population
por: Waldo, Daniel R.
Publicado: (1987)

Spending on and Use of Clinician-Administered Drugs in Medicare
por: Hyland, Megan F., et al.
Publicado: (2023)

Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
por: San-Juan-Rodriguez, Alvaro, et al.
Publicado: (2021)

Changes in Out-of-Pocket Spending and Catastrophic Health Care Expenditures Associated With Medicare Eligibility
por: Scott, John W., et al.
Publicado: (2021)

Medicare risk contracting: Determinants of market entry
por: Porell, Frank W., et al.
Publicado: (1990)

Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists
por: Dickson, Sean R., et al.
Publicado: (2023)

Freestanding Emergency Department Entry and Market‐level Spending on Emergency Care
por: Ho, Vivian, et al.
Publicado: (2019)

Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023)

Drug Coverage, Utilization, and Spending by Medicare Beneficiaries with Heart Disease
por: Sharma, Ravi, et al.
Publicado: (2003)

State-Level Variation in Medicare Spending
por: Gage, Barbara, et al.
Publicado: (1999)

Sources of Low-Value Care Received by Medicare Beneficiaries and Associated Spending Within US Health Systems
por: Chant, Emma D., et al.
Publicado: (2023)

Changes in Medicare Accountable Care Organization Spending, Utilization, and Quality Performance 2 Years Into the COVID-19 Pandemic
por: Yan, Brandon W., et al.
Publicado: (2023)

Trends in Use of and Medicare Spending on Short-Course Radiotherapy for Lymphomas From 2015 to 2019
por: Tringale, Kathryn R., et al.
Publicado: (2022)

Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019
por: Erath, Alexandra, et al.
Publicado: (2020)

Medicare Part D on the Front Line
por: Collins, Andrew
Publicado: (2006)

Identifying drugs with the greatest increases and decreases in spending per beneficiary using Medicare Part D: A cross-sectional study
por: Hodzic-Santor, Benazir, et al.
Publicado: (2023)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

The Challenge of Medicare Part D for Community Pharmacies
por: Stone, Devin
Publicado: (2009)

Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D
por: Naci, Huseyin, et al.
Publicado: (2023)

National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019
por: Troy, Aaron, et al.
Publicado: (2021)

Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
por: Essa, Mohammed, et al.
Publicado: (2023)

The impact of weight loss among seniors on Medicare spending
por: Thorpe, Kenneth E, et al.
Publicado: (2013)

Medicare physicians' services: The composition of spending and assignment rates
por: Burney, Ira, et al.
Publicado: (1985)

Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage
por: Chua, Kao-Ping, et al.
Publicado: (2021)

Evaluation of Spending Differences Between Beneficiaries in Medicare Advantage and the Medicare Shared Savings Program
por: Parikh, Ravi B., et al.
Publicado: (2022)

Uptake and Competition Among Biosimilar Biological Products in the US Medicare Fee-for-Service Population
por: Kozlowski, Steven, et al.
Publicado: (2022)

Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis
por: Li, David G, et al.
Publicado: (2019)

Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals
por: Li, Yufei, et al.
Publicado: (2022)

Biosimilars: Company Strategies to Capture Value from the Biologics Market
por: Calo-Fernández, Bruno, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2ikogfoigamnlnpsknp72dh0ch